Saif Muhammad Wasif
Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine, Feinstein Institute for Medical Research, Lake Success, NY, USA.
JOP. 2021;22(3):70-79. Epub 2021 May 31.
Pancreatic adenocarcinoma is a devastating malignancy, associated with a grim prognosis, due to its silent presentation and lack of diagnostic tests. In addition, treatment options are limited to few agents, such as 5-FU, irinotecan, oxaliplatin, gemcitabine and nab-paclitaxel.
We performed a literature search for relevant published clinical trials, abstracts of trials in progress and ongoing or planned trials for the treatment of APC using Pubmed.com, ClinicalTrials.gov and American Society of Clinical Oncology (ASCO) abstract search as sources. We present an in-depth analysis of the phase I-III clinical trials determining the role and efficacy of different modalities. We also describe rationale for future investigation.
Despite advances in first-line and second-line therapies for APC, median OS remains short of a year. We need collaborative efforts between the cooperative groups, institutions, community practices and industry to work together in enrolling these patients in clinical trials. In addition to use new technologies, such as organoids, we must pay attention to the palliative aspect of care for these patients from the beginning including nutritionist, social worker and supportive care health providers to assist with goals of care, symptom management and end of life discussions.
胰腺腺癌是一种极具破坏性的恶性肿瘤，因其症状隐匿且缺乏诊断性检查，预后很差。此外，治疗选择仅限于少数几种药物，如5-氟尿嘧啶、伊立替康、奥沙利铂、吉西他滨和纳米白蛋白结合型紫杉醇。
我们使用Pubmed.com、ClinicalTrials.gov和美国临床肿瘤学会（ASCO）摘要搜索作为来源，对已发表的相关临床试验、正在进行的试验摘要以及正在进行或计划进行的治疗胰腺腺癌的试验进行了文献检索。我们对确定不同治疗方式的作用和疗效的I-III期临床试验进行了深入分析。我们还描述了未来研究的理论依据。
尽管胰腺腺癌的一线和二线治疗取得了进展，但中位总生存期仍不足一年。我们需要合作组、机构、社区医疗机构和行业之间共同努力，让这些患者参与临床试验。除了使用类器官等新技术外，我们必须从一开始就关注这些患者的姑息治疗方面，包括营养师、社会工作者和支持性护理健康提供者，以协助制定护理目标、症状管理和临终讨论。
